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B
y next summer, more than 40% 
of Streptococcus pneumoniae strains 
in the United States will resist 
both penicillin and erythromycin, 
according to a recent prediction from 
the Harvard School of Public Health. 
The forecast, based on mathematical 
modeling, was published in the spring 
of 2003. It’s too early to tell whether 
that prediction is precisely on track, 
according to the senior author on 
that paper, Marc Lipsitch. But no one 
doubts that multidrug resistance in 
this common bug—responsible for 
diseases that range from sinus trouble 
and ear infections to meningitis and 
pneumonia—is speeding up. 
It is the certain fate of all 
antibacterials to be fought off 
eventually by the pathogens they target. 
The fact that the process is accelerating 
has been alarming public health 
ofﬁ  cials for some time, especially in the 
United States. We need new ways to 
defeat disease, and we will need them 
forever. 
Tried and True—and Tired?
Antibiotics have traditionally been 
plucked from nature’s battleground. 
For billions of years, tiny organisms 
have engaged in an arms race, hurling 
toxic molecules at each other in 
the struggle to prosper. Nearly all 
of today’s antibiotics are versions of 
weapons long wielded by microbes and 
fungi. Chemical synthesis of entirely 
human-created antibiotics has so far 
yielded only ﬂ  uoroquinolones, a group 
of broad-spectrum antibiotics that 
includes Cipro, which became famously 
scarce during the 2001 anthrax scare, 
and linezolid (trade-named Zyvox), 
which is effective against some resistant 
strains of Staphylococcus, Streptococcus, 
and Enterococcus. 
The usual way to ﬁ  nd a new 
antibiotic has been laborious screening 
of immense libraries of compounds, 
natural and otherwise. Some argue 
that screening chemical libraries is 
approaching a deadend. There may be 
diminishing returns from screening, 
but it’s not quite dead yet: in October, 
researchers at the University of 
Wisconsin at Madison reported a new 
class of bacterial RNA polymerase 
inhibitors with antibiotic potential. 
They were found by screening for 
molecules that prevent Escherichia coli 
from transcribing RNA.
Christopher T. Walsh of Harvard 
Medical School says screening’s 
problem may be simply that libraries 
aren’t good enough. Marine organisms 
have not been studied well, he points 
out, and 90% of organisms in the 
biosphere can’t be cultured in standard 
ways. He says, “We’re missing 90% of 
them every time we go and look in 
nature.”
Walsh is doing his bit to create new 
libraries. He and his colleagues have 
recently employed combinatorial 
biosynthesis to learn how to use part 
of the machinery for assembling 
cyclic peptide antibiotics to control 
their architecture. The result was 
a small library of natural product 
analogs, some of which have improved 
antibiotic activity against common 
bacterial pathogens. “There are dozens 
of such enzymatic domains that in 
principle one could clone, express, 
and test with other substrates. I view 
that as the kind of thing we should 
do,” he says. For example, Walsh 
suggests, it is a reasonable approach 
to second-generation improvement 
of daptomycin, the antibiotic most 
recently approved for sale in the 
United States.
Improving on Nature
Walsh collaborates with Chaitan 
Khosla of Stanford University 
on ﬁ  nding ways to make existing 
antibiotics better. They are studying 
biosynthesis of rifamycin, an antibiotic 
that is increasingly less effective 
against its prime target, tuberculosis 
(TB) (see Figure 1). “In the course 
of learning about that pathway, we’ve 
learned a few interesting things lately 
about how that molecule is initiated, 
and we’re trying to apply it in other 
contexts, especially in the context of 
erythromycin biosynthesis,” Khosla 
says. The idea would be to make a 
molecule that might be more effective 
against bacteria that are becoming 
resistant to rifamycin—and are already 
naturally resistant to molecules like 
erythromycin.
“Basically, what we do is to try and 
ﬁ  gure out new ways to hijack the 
biosynthesis of antibiotics in nature 
so as to modify their structures with 
the goal of improving them,” Khosla 
explains. He works with an important 
class of natural antibiotics called 
polyketides that have generated dozens 
of drugs, including erythromycin.
Polyketides are secondary 
metabolites (which give their producers 
a competitive advantage in their 
environment) produced mostly by 
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Figure 1. TB Drug Resistance
This 40-year-old Estonian truck driver’s 
TB is resistant to drugs and his right 
lung was removed three days before this 
picture was taken. (Photograph by WHO/
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bacteria and fungi and made by a 
complex and structurally diverse family 
of enzymes called polyketide synthases 
(see the primer by David Hopwood 
in this issue of PLoS Biology). Among 
them are the anthracyclines, a group of 
anticancer drugs and antibacterials that 
includes tetracycline. In this issue of 
PloS Biology, Khosla and his colleagues 
report that they can make selective 
positional modiﬁ  cations in existing 
anthracycline antibiotics by starting in 
a different way with a different starting 
molecule. The molecule came from 
a natural anthracycline antibiotic, an 
estrogen receptor antagonist called 
R1128. R1128 is made via two modules 
of enzymes that work sequentially; the 
ﬁ  rst module starts the process, and 
the second completes it. This division 
of labor permitted the researchers to 
tack the ﬁ  rst R1128 module onto two 
other enzyme systems, thus engineering 
completely new anthracyclines. Some 
were more active in two types of assays 
than the natural parent molecule. “One 
setting was an assay on an estrogen-
sensitive cancer cell line. Another 
setting was an assay to probe activity of 
an enzyme that’s of particular interest 
in Type 2 diabetes, called glucose-6-
phosphate translocase.” The work also 
revealed fundamental mechanistic 
features of the polyketide synthases, 
Khosla says.
The researchers didn’t study the 
new anthracyclines’ effects on bacteria, 
but Khosla notes that the general 
principle should apply to other classes 
of compounds, although the details of 
how it’s implemented will vary from 
system to system. He says, “The upshot 
of this paper is that it is now possible to 
modify a particular methyl group in just 
about any anthracycline antibiotic.”
Finding New Targets
Instead of searching for new 
antibiotics by modifying existing ones, 
some researchers are trying something 
completely different—ﬁ  rst ﬁ  nding the 
most vulnerable targets in a bacterium 
and then designing something that hits 
one or more of them hard. “You have 
to understand a helluva lot more about 
how these little cells work. In fact, we 
think we understand a lot, but I think 
we can understand almost everything 
now that we have all the genomes,” says 
Lucy Shapiro of Stanford University 
School of Medicine. While having 
full genome sequences—more than 
100 microbe sequences have been 
completed—is essential, Shapiro 
believes that knocking outs genes 
galore to ﬁ  nd out which ones are 
necessary and going after them all is 
not a sensible strategy. She observes, 
“People have been doing that for a 
while with absolutely no success. That’s 
really going after the problem with a 
Howitzer instead of with an intelligent 
approach.”
So instead of screening libraries of 
existing compounds, Shapiro prefers 
using structural information about 
drug targets or their natural ligands 
to create new drugs, an approach 
known as rational drug design. And 
instead of looking at all essential genes 
in a bacterium and choosing one to 
target, she and her colleagues look at 
genetic circuitry that controls the cell 
cycle, the pathway that coordinates 
cell growth and differentiation. They 
have identiﬁ  ed key control points, or 
nodes, in the circuitry for their favorite 
study subject, Caulobacter crescentus. 
Thus, they have found critical genes 
encoding proteins that control several 
critical functions in the cell. Their ﬁ  rst 
candidate was an essential enzyme, a 
methyltransferase called CcrM, that 
prevents a particular piece of DNA 
from being expressed in a cell by 
tagging it with a methyl group.
Antibiotic discovery is all chemistry, 
Shapiro says, which is why she joined 
with biochemist Stephen J. Benkovic 
of Pennsylvania State University. They 
didn’t know the structure of CcrM, 
Benkovic explains, but the literature 
about other methyltransferases 
suggested that the adenine molecule, 
which is the substrate for CcrM within 
DNA, binds to a speciﬁ  c region of the 
enzyme. 
The researchers designed adenine-
like molecules that would bind to 
CcrM and then developed inhibitors. 
Benkovic says, “We already knew what 
kind of structure we wanted, and we 
simply ﬁ  ne-tuned it.” They worked 
their way through 1,000  inhibitor 
candidates, ending up with a small 
subset—no more than about 20—that 
not only inhibited CcrM, but also killed 
Caulobacter very quickly.
And not only inoffensive Caulobacter. 
The compounds knock out other 
gram-negative bacteria, such as 
the pathogens Brucella abortus and 
Francisella tularensis. Some even killed 
off anthrax, a big surprise because 
it is gram-positive and so has much 
thicker cell walls than gram-negative 
bacteria. The researchers undertook 
an exhaustive series of experiments 
to identify which gram-positive 
bacteria would be affected by which 
compounds. The list of sensitive 
pathogens now includes multidrug-
resistant Streptococcus, Staphylococcus, and 
Mycobacterium tuberculosis.
More recently, Shapiro reports, 
they have demonstrated efﬁ  cacy 
against rats infected with anthrax or 
multidrug-resistant Staph, although the 
compounds save only about 60% of the 
rats at present. She notes, “So we have a 
long way to go. But this has proven that 
if you go after something using some 
rational approach instead of hit-and-
miss, you’ll probably have more success 
than by the other method.”
Benkovic points out that theirs is 
an entirely new class of compounds, 
small molecular weight compounds 
that can be made in a few steps. He 
says, “They don’t look like the normal 
antibiotic, so that’s why I think they’re 
fairly unique.” The basic research 
was done under a grant from the 
Defense Advanced Research Projects 
Agency (DARPA), the United States 
Department of Defense’s (DOD) 
central research and development 
organization, and once the researchers 
realized they wanted to develop 
drugs against three agents that have 
been considered bioterrorism threats 
— Brucella, tularensis, and anthrax — 
they established a separate operation, 
Anacor Pharmaceuticals, which is 
developing them with DOD funding 
and without Shapiro. In her Stanford 
lab, she continues her fundamental 
research to deﬁ  ne the complete genetic 
circuitry of Caulobacter, hoping to 
identify additional nodes in the circuit. 
She says, “I am not doing it to develop 
antibiotics; that’s what comes out of 
the work. My goal is to understand how 
the cell works. I think a lot of studies 
in pathogenesis should not be just to 
understand pathogenic organisms, but 
to understand the complete network 
of regulatory mechanisms that controls 
the bacterial cell.”
Phage Therapy
The most radical approach to new 
antibiotics may be the resurrection of 
an old idea: bacteriophage therapy (see 
Figure 2). Late in the 19th century, 
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some of India’s sacred rivers combated 
cholera. Some years later, the active 
agents were identiﬁ  ed as viruses that 
infected bacteria. Such viruses are 
called bacteriophage, or phage for 
short. There were reports of phage 
success against dysentery, typhoid, and 
plague, and bacteriophage therapy had 
a brief heyday, especially in the 1920s. 
Results on other diseases were mixed, 
and with the appearance of antibiotics, 
phage therapy became unfashionable 
in the United States, although it has 
continued in Russia and Eastern 
Europe.
Phage were the model organisms 
of choice for genetics research in 
the 1930s and 1940s, but became less 
fashionable as research tools when 
investigators moved on to eukaryotes. 
A few held on, like Ry Young of Texas 
A&M University, who has made phage-
induced cell lysis his life’s work. “The 
cell is basically genetically dead as 
soon as the phage goes in there, but it 
will keep living as sort of an infected 
zombie for as long as the phage wants 
it to, with virus particles accumulating 
inside the cell,” he explains. “Only 
when the phage is ready and has 
decided that it’s the right time will it 
pull the trigger. And the cell blows up.” 
The freed phage then spew forth to 
infect new cells.
Antibiotic resistance has led to new 
interest in phage therapy by several 
small biotech companies. Young 
continues basic research at Texas 
A&M, but has also joined one of them, 
GangaGen, providing bacteriophage 
expertise to its labs.
Phage do kill pathogenic bacteria 
effectively, and they do it without 
penetrating human cells, which 
they can’t even recognize. So what 
is keeping phage therapy out of the 
clinic? Problems that some doubt can 
be overcome. 
Because bacteria develop resistance 
to phage rapidly, phage therapy 
companies will need to direct cocktails 
against a single pathogen, according 
to Vincent Fischetti at The Rockefeller 
University. Phage are also antigenic, 
and the antibodies they stimulate 
will neutralize their effects during 
subsequent treatment, he says. But 
the chief problem appears to be 
regulatory—regulatory in the political, 
rather than the genetic, sense. When 
bacteriophage package their DNA, they 
occasionally include varying amounts of 
their hosts’ DNA, too. This miscellany, 
Fischetti points out, is likely to make 
the Food and Drug Administration 
unhappy. “Phage normally are very 
fragile, their tails break, so lot-to-lot 
homogeneity could be a problem too,” 
he adds. “So even though it will work, 
I think they’ll have an uphill battle.” 
Phage may well enter agricultural or 
veterinary use, he predicts, but are 
probably not going to be available to 
patients in the United States any time 
soon. 
 Fischetti chose a different approach 
to phage therapy. It does not rely on 
phage themselves, but on enzymes 
that phage produce to smash their way 
out of their host bacteria so they can 
infect new hosts. He and his colleagues 
employ these enzymes externally to 
kill bacteria. He reports, “We now have 
enzymes that will kill Strep pyogenes, 
pneumococci, Strep pneumoniae, Bacillus 
anthracis, Enterococcus faecalis, and group 
B Strep. The beauty of these enzymes 
is that they are targeted killing. You 
only kill the organism you intend to 
kill, without destroying or affecting 
the surrounding organisms that are 
necessary for health.”
The enzymes can be loaded into a 
nasal spray that wipes out pathogens 
such as Pneumococcus, Staphylococcus, 
and group A Strep on contact with 
mucous membranes. The strategy 
might prevent bacterial infections 
from spreading in close quarters 
like hospitals, nursing homes, and 
daycare centers. Fischetti says, “Clinical 
trials would tell us how often we 
had to treat, but more important, 
we’d have a reagent that could treat 
people who walk out the door of the 
hospital to eliminate or reduce the 
transmission of resistant organisms into 
the community. We don’t have that 
capability right now.”
Fischetti and his colleagues have 
moved on to using the enzymes 
systemically to wipe out Bacillus 
anthracis spores, preventing them from 
germinating and seething through the 
bloodstream, producing deadly toxins. 
An IV drip would be started after 
exposure to the spores. The method, 
Fischetti reports, is already successful 
in mice; clinical trials will determine 
how long treatment must be continued, 
perhaps a week or so. They have also 
eliminated septicemia from pneumocci 
with the same intravenous method. 
Up to now the enzymes must 
make contact with bacteria to kill, 
but Fischetti is hoping that a new 
generation of engineered enzymes will 
be able to kill pathogens inside cells 
too. A second disadvantage is that they 
are effective only against gram-positive 
bacteria, although that group includes 
many vicious pathogens. 
But phage enzymes seem to offer 
one very big advantage: resistance 
to them has yet to develop. Fischetti 
says, “We’ve tried very hard to identify 
resistant bacteria, but so far we haven’t 
found resistant organisms in all three 
of the enzymes we’re working with. It 
appears to be a very rare event, much 
rarer than resistance to antibiotics.” 
Fischetti cautions against expecting 
that gladsome state to last forever, but 
he points out that even if widespread 
resistance takes the same 40 or 50 years 
that antibiotics required to become 
signiﬁ  cantly resistant, phage enzymes 
could buy researchers decades for 
inventing other approaches.
Antibiotics in the 21st Century
There is no shortage of ideas for 
unearthing new antibiotic candidates. 
Why are they so slow to enter medical 
practice? The bottleneck, researchers 
agree, lies in the development 
process of turning them into effective 
therapies. Several researchers blame 
DOI: 10.1371/journal.pbio.0020053.g002
Figure 2. Phage
Negative stain electron micrograph of 
the gamma phage from which the PlyG 
lytic enzyme was cloned for use to control 
B. anthracis. (Photograph courtesy of 
Vincent Fischetti and Raymond Schuch, 
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the big pharmaceutical companies that 
got so big by leading the way to new 
drugs for battling infectious disease, 
but in recent years have dropped out. 
Fischetti complains, “These are the 
big companies that have the money to 
develop antiinfectives, but they leave it 
to small biotech companies, and it’s not 
going to happen as rapidly as it should. 
I think it’s really unconscionable for 
these big companies to drop the ball 
because it’s not going to be a billion-
dollar market for them and that’s what 
they’re looking for.”
Half a billion at least, says Francis 
Tally, a big pharmaceuticals veteran 
who is now chief scientiﬁ  c ofﬁ  cer at 
Cubist Pharmaceuticals, a biotech 
company located in Lexington, 
Massachusetts. According to Tally, 
Cubist produced daptomycin, approved 
in September 2003, by licensing it 
from Eli Lilly, which shelved the 
new compound after concluding its 
potential market was only $250 million.
But, Tally argues, the size of the 
market is not the only barrier to new 
antibiotics. Combinatorial chemistry 
and the genomics revolution have 
simply not delivered on their early 
promise. “The pipeline is very dry,” 
he says. “There’s been a real lag at the 
basic research level.”
“Antibiotic discovery is hard,” Shapiro 
says. “It’s a huge long process to get a 
decent antibiotic.” Walsh agrees. “It’s 
easier to ﬁ  nd inhibitors of particular 
enzymes for particular processes—and 
a very long road to convert that into 
something for development.” 
In the meantime, there is a rising 
clamor to slow down the rate at which 
bacteria develop resistance. Doctors are 
exhorted to cut back on prescribing 
antibiotics and decline to prescribe 
for viral diseases, which antibiotics 
can’t combat, even when their patients 
badger them. 
But even if antibiotic consumption 
slowed, we will still need new 
antibiotics. “I always say it’s not a matter 
of if, it’s only a matter of when,” says 
Walsh. “There will always be a need for 
new antibiotics because the clock starts 
ticking on the useful lifetime of any 
antibiotic once you start to use it. That 
cannot be argued.”  
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